US equities |
NVDA $237.58 ▲+1.55% MU $1,058.50 ▼-1.52% SPCX $163.90 ▲+3.11% MSFT $528.62 ▲+2.14% TSLA $374.20 ▲+0.97% INTC $116.63 ▼-2.26% SNDK $1,724.59 ▲+0.27% AMD $630.22 ▼-0.58%
FinancialContent

Articles published by Oncotelic Therapeutics, Inc.

News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC
News headline image
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Tickers OTLC